ReviewGenetics in medicine : official journal of the American College of Medical Genetics2018
A proposed approach to accelerate evidence generation for genomic-based technologies in the context of a learning health system.
Review in Genetics in medicine : official journal of the American College of Medical Genetics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04331535 (Pragmatic Randomized Trial of Polygenic Risk Scoring for Common Diseases in Primary Care), which is not on this map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Pragmatic Randomized Trial of Polygenic Risk Scoring for Common Diseases in Primary Care
Who cites it
16 citing papers in PubMed.
- Exploring Factors That Impact Genetic Counseling Referral and Uptake Using Learning Health Approaches.Learning health systems · 2026Article
- Considering Clinical Implementation of Polygenic Scores in Hereditary Cancer Risk Assessment: Recipients' Perspectives on Influencing Factors and Strategies.The patient · 2025Article
- An Assessment of Real-World Evidence and Other Sources Supporting Payer Coverage Decisions for Pharmacogenomic Testing in Psychiatry.Journal of personalized medicine · 2025Article
- The power of personas: Exploring an innovative model for understanding stakeholder perspectives in an oncology learning health network.Learning health systems · 2025Article
- Effect of clinical decision support for severe hypercholesterolemia on low-density lipoprotein cholesterol levels.NPJ digital medicine · 2024Article
- Article
- Towards a Responsible Transition to Learning Healthcare Systems in Precision Medicine: Ethical Points to Consider.Journal of personalized medicine · 2021Review
- Opportunities and challenges for the computational interpretation of rare variation in clinically important genes.American journal of human genetics · 2021Review
- Governing Personalized Health: A Scoping Review.Frontiers in genetics · 2021Article
- Personalized early detection and prevention of breast cancer: ENVISION consensus statement.Nature reviews. Clinical oncology · 2020Review
- Generating evidence for precision medicine: considerations made by the Ubiquitous Pharmacogenomics Consortium when designing and operationalizing the PREPARE study.Pharmacogenetics and genomics · 2020Article
- Improving recommendations for genomic medicine: building an evolutionary process from clinical practice advisory documents to guidelines.Genetics in medicine : official journal of the American College of Medical Genetics · 2019Review
- Building evidence and measuring clinical outcomes for genomic medicine.Lancet (London, England) · 2019Review
- Classification, Ontology, and Precision Medicine.The New England journal of medicine · 2018Review
- Enhancing diversity to reduce health information disparities and build an evidence base for genomic medicine.Personalized medicine · 2018Article
- A collaborative translational research framework for evaluating and implementing the appropriate use of human genome sequencing to improve health.PLoS medicine · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Genomic technologies should demonstrate analytical and clinical validity and clinical utility prior to wider adoption in clinical practice. However, the question of clinical utility remains unanswered for many genomic technologies. In this paper, we propose three building blocks for rapid generation of evidence on clinical utility of promising genomic technologies that underpin clinical and policy decisions. We define promising genomic tests as those that have proven analytical and clinical validity. First, risk-sharing agreements could be implemented between payers and manufacturers to enable temporary coverage that would help incorporate promising technologies into routine clinical care. Second, existing data networks, such as the Sentinel Initiative and the National Patient-Centered Clinical Research Network (PCORnet) could be leveraged, augmented with genomic information to track the use of genomic technologies and monitor clinical outcomes in millions of people. Third, endorsement and engagement from key stakeholders will be needed to establish this collaborative model for rapid evidence generation; all stakeholders will benefit from better information regarding the clinical utility of these technologies. This collaborative model can create a multipurpose and reusable national resource that generates knowledge from data gathered as part of routine care to drive evidence-based clinical practice and health system changes.
Indexed as
Identifiers
28796238What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.